Remove Genomics Remove Research Remove RNA
article thumbnail

Short reads, big impact: How genomics is revolutionising cancer research

pharmaphorum

Discover how genomics is transforming cancer research through the study of DNA, RNA, and ctDNA. Learn about the latest breakthroughs in the field in this insightful short read.

Genome 126
article thumbnail

The revolutionary impact of understanding genomics

Drug Discovery World podcast

This is the latest episode of the free DDW narrated podcast, titled The revolutionary impact of understanding genomics, which covers two articles written for DDW Volume 24 Issue 3, Summer 2023. In the first article, Evan Floden, CEO of Seqera Labs, examines how data sharing platforms are impacting cancer and genomics research.

Genome 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ochre Bio raises funds to develop RNA therapies for liver diseases

Pharmaceutical Technology

Biotechnology company Ochre Bio has raised $30m in a Series A financing round to develop RNA therapies for chronic liver diseases. It also intends to turn the insights from its research into RNA-based drug candidates, and they will be tested in human livers at the company’s recently opened ‘Liver ICUs’ in the US.

RNA 130
article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.

Genome 129
article thumbnail

Verge Genomics takes AI-sourced drug for ALS into clinic

pharmaphorum

Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing. The post Verge Genomics takes AI-sourced drug for ALS into clinic appeared first on.

Genome 136
article thumbnail

Investment fuels AI-driven development of breakthrough genomic medicines

pharmaphorum

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 105
article thumbnail

BioTuring enters collaboration to enable detailed single-cell RNA research

pharmaphorum

Research into single-cell sequencing has been boosted with Single Cell Discoveries and BioTuring joining forces to refine the process. A rapidly growing field of research, single-cell RNA sequencing is vital for those working in areas such as oncology, immunology, and neuroscience.

RNA 72